GSK catalyst calendar
Clinical trials led by listed companies, by the completion date the sponsor registered on ClinicalTrials.gov, soonest first, from today. Most future dates are the sponsor's estimate and can move.
November 2026
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Nov 19, 2026Sponsor estimate | NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, Bacterial | GSKLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Nov 19, 2026Sponsor estimatePhase 1NCT07428759Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 YearsGlaxoSmithKline · Pneumonia, BacterialActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
December 2026
- Primary completion Dec 2026Sponsor estimatePhase 1/Phase 2NCT06258018Niraparib and Temozolomide in Patients GlioblastomaArmando Santoro, MD · Glioma, MalignantNot yet recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2026Sponsor estimatePhase 1NCT07464314A Study on the Safety and Immune Response of Investigational mRNA Seasonal Flu/COVID-19 Combination Vaccine in AdultsGlaxoSmithKline · Influenza, Human+COVID-19RecruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 16, 2026Sponsor estimatePhase 1NCT06154837A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary DiseaseGlaxoSmithKline · Pulmonary Disease, Chronic ObstructiveActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT03945721A Phase I Study of Niraparib Administered Concurrently With Postoperative RT in Triple Negative Breast Cancer PatientsMassachusetts General Hospital · Triple Negative Breast CancerActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 31, 2026Sponsor estimatePhase 1NCT04446351Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid TumorsGlaxoSmithKline · NeoplasmsActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
January 2027
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Jan 3, 2027Sponsor estimate | NCT03830918Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With...Jonsson Comprehensive Cancer Center · Advanced Malignant Solid Neoplasm | GSKCollaborator | Phase 1/Phase 2 | Active, not recruiting | Locked | Locked | Locked |
| Jan 12, 2027Sponsor estimate | NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy Participants | GSKLead | Phase 1 | Not yet recruiting | Locked | Locked | Locked |
| Jan 22, 2027Sponsor estimate | NCT07053384A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in...ViiV Healthcare · HIV Infections | GSKLead | Phase 1 | Active, not recruiting | Locked | Locked | Locked |
- Primary completion Jan 3, 2027Sponsor estimatePhase 1/Phase 2NCT03830918Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With...Jonsson Comprehensive Cancer Center · Advanced Malignant Solid NeoplasmActive, not recruitingGSKCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 12, 2027Sponsor estimatePhase 1NCT07862114A Study to Investigate the Effect of Omeprazole and Cyclosporine on Velzatinib in Healthy ParticipantsGlaxoSmithKline · Healthy ParticipantsNot yet recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 22, 2027Sponsor estimatePhase 1NCT07053384A Study to Investigate the Use of VH3810109 With or Without Fostemsavir (FTR) to Reduce the Size and Activity of the Viral Reservoir in...ViiV Healthcare · HIV InfectionsActive, not recruitingGSKLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 9 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScannerHow to read this calendar
Completion dates as registered on ClinicalTrials.gov by the sponsor, for trials Signal8 links to a listed company. Most future dates are the sponsor's estimate and move. A completion date is when the last participant is measured, not when results are announced.
The window starts today. A date the sponsor registered to the day is listed when it falls inside the window; a date that has already passed is never listed as upcoming, even when the sponsor has not updated it yet. A date registered to the month only (shown as, say, Dec 2026) could be any day of that month, so it is listed only when the whole month falls inside the window. TrialScanner never adds a day the sponsor did not register.
By default the list shows trials where a listed company is the lead sponsor. Trials a listed company only collaborates on (as a partner, drug supplier or contract research organization) are added with the role filter, and every company is labelled Lead or Collaborator.
Free readers see the first 25 trials of any filter and windows up to 90 days, with the trial, phase, status, sponsor and primary completion. Enrollment, interventions, the start and completion dates, longer windows and later pages are part of the plan. See the methodology.